| Display title | Chemistry:Saroglitazar |
| Default sort key | Saroglitazar |
| Page length (in bytes) | 8,814 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 820675 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>NBrush |
| Date of page creation | 03:14, 9 March 2024 |
| Latest editor | imported>NBrush |
| Date of latest edit | 03:14, 9 March 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes... |
